# EDGAR Filing Document

**Accession Number:** 0001560009
**File Stem:** 0001104659-25-084813
**Filing Date:** 2025-8
**Character Count:** 7268
**Document Hash:** f8ae9f86297fee8973a4559ce3bcdd57
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-084813.hdr.sgml**: 20250828

**ACCESSION NUMBER**: 0001104659-25-084813

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250828

**EFFECTIVENESS DATE**: 20250828

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Versant Venture Management, LLC
- **CENTRAL INDEX KEY:** 0001560009

**ORGANIZATION NAME:**
- **EIN:** 954767945
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-16849
- **FILM NUMBER:** 251274252

**BUSINESS ADDRESS:**
- **STREET 1:** ONE SANSOME STREET, SUITE 1650
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94104
- **BUSINESS PHONE:** 650-233-7877

**MAIL ADDRESS:**
- **STREET 1:** ONE SANSOME STREET, SUITE 1650
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94104

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001560009

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Versant Venture Management, LLC

**Address:** One Sansome Street, San Francisco, CA 94104

**Telephone number:** 415-801-8100

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-16849

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                           | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Adverum Biotechnologies, Inc. | 00773U108 | 06/17/2025     | To approve, on an advisory basis, the compensation of our named executive officers                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |         506821 |                0 | FOR         |                                   506821 | FOR                         |  |
| CRISPR Therapeutics AG        | H17182108 | 06/05/2025     | Binding vote on maximum non-performance-related compensation for members of the Board of Directors from the 2025 Annual General Meeting to the 2026 annual general meeting of shareholders | SECTION 14A SAY-ON-PAY VOTES |         500028 |                0 | FOR         |                                   500028 | FOR                         |  |
| CRISPR Therapeutics AG        | H17182108 | 06/05/2025     | Binding vote on maximum equity for members of the Board of Directors from the 2025 Annual General Meeting to the 2026 annual general meeting of shareholders                               | SECTION 14A SAY-ON-PAY VOTES |         500028 |                0 | FOR         |                                   500028 | FOR                         |  |
| CRISPR Therapeutics AG        | H17182108 | 06/05/2025     | Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2025 to June 30, 2026                                                     | SECTION 14A SAY-ON-PAY VOTES |         500028 |                0 | FOR         |                                   500028 | FOR                         |  |
| CRISPR Therapeutics AG        | H17182108 | 06/05/2025     | Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2025                                                         | SECTION 14A SAY-ON-PAY VOTES |         500028 |                0 | FOR         |                                   500028 | FOR                         |  |
| CRISPR Therapeutics AG        | H17182108 | 06/05/2025     | Binding vote on maximum equity for members of the Executive Committee from the 2025 Annual General Meeting to the 2026 annual general meeting of shareholders                              | SECTION 14A SAY-ON-PAY VOTES |         500028 |                0 | FOR         |                                   500028 | FOR                         |  |
| CRISPR Therapeutics AG        | H17182108 | 06/05/2025     | Non-binding advisory vote on the 2024 Compensation Report                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |         500028 |                0 | FOR         |                                   500028 | FOR                         |  |
| CRISPR Therapeutics AG        | H17182108 | 06/05/2025     | Non-Binding Advisory Vote on the Compensation Paid to the Company's Named Executive Officers Under U.S. Securities Law Requirements                                                        | SECTION 14A SAY-ON-PAY VOTES |         500028 |                0 | FOR         |                                   500028 | FOR                         |  |
| Repare Therapeutics, Inc.     | 760273102 | 06/17/2025     | Approval, on a Non-Binding, Advisory Basis, of the Compensation of our Named Executive Officers                                                                                            | SECTION 14A SAY-ON-PAY VOTES |        2646657 |                0 | FOR         |                                  2646657 | FOR                         |  |
| Skye Bioscience, Inc.         | 83086J200 | 06/06/2025     | To approve, on an advisory basis, the compensation of our named executive officers                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |        2007704 |                0 | FOR         |                                  2007704 | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** Versant Venture Management, LLC

**By (Signature):** Max Eisenberg

**By (Printed Signature):** Max Eisenberg

**By (Title):** Chief Operating Officer

**Date:** 08/28/2025